Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s ...
“To the best of our team's knowledge, this project represents the first time an Alabama medical center has examined deep brain stimulation for depression,” said Matthew Macaluso, D.O., director of the ...
Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression. The company previously collected green lights for ...
ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain ...
Medical Device Network on MSN
Abbott touts neuromodulation portfolio’s long-term benefits
Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...
AUSTIN (KXAN)- Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking implantable device may offer new hope. Depression affects ...
Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, ...
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results